Creating new treatments for respiratory viruses by targeting specific proteins in host cells
Developing broad-based treatments for respiratory viruses by targeting host cell TTSPs
This study is exploring a new treatment that could help prevent respiratory viruses like COVID-19 and the flu by blocking the way these viruses enter our cells, and it's designed for anyone looking for better ways to stay healthy during cold and flu season.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cornell University NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project ID | NIH-11028136 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of treatment for respiratory viruses, including COVID-19 and influenza, by targeting specific proteins in human cells that viruses need to enter. The approach uses small molecules that mimic peptides, which are easier to produce and can potentially be used to prevent infections. The researchers will conduct studies in living organisms to test how well these treatments work against virus transmission. This method aims to be effective against a wide range of viruses and may adapt to new strains without leading to resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for respiratory infections, such as those with underlying health conditions or those in close contact with infected individuals.
Not a fit: Patients who are not at risk for respiratory infections or those who have already been vaccinated against the targeted viruses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments that prevent respiratory virus infections, improving public health outcomes.
How similar studies have performed: Previous research has shown promise in targeting host cell proteins to combat viral infections, indicating that this approach may be effective.
Where this research is happening
Ithaca, United States
- Cornell University — Ithaca, United States (Active)
Researchers
- Principal investigator: Whittaker, Gary R — Cornell University
- Study coordinator: Whittaker, Gary R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.